Showing posts with label blood brain barrier. Show all posts
Showing posts with label blood brain barrier. Show all posts

Thursday, October 4, 2018

Getting into an Alzheimer's brain

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two




A handful of Alzheimer's patients signed up for a bold experiment: They let scientists beam sound waves into the brain to temporarily jiggle an opening in its protective shield, called the "Blood-Brain Barrier". This is how it works. 




Charlottesville, Virginia – The results of the first ever clinical trial of focused ultrasound to open the blood-brain barrier (BBB) in patients with Alzheimer’s disease were published in Nature Communications and also presented at the Alzheimer’s Association International Conference (AAIC)


The pilot trial demonstrated the feasibility and preliminary safety of focally, reversibly, and repetitively opening the BBB. 

Delivering Drugs to the Alzheimer's Brain

“This groundbreaking trial is the first small but critically important step in a process that could potentially lead to a novel approach to delivering drugs to the brain to treat Alzheimer's disease,” said Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation. “This study widens the horizon of possibility for focused ultrasound to become a treatment option for many neurological disorders by demonstrating that the technology can, in fact, be used to open the blood-brain barrier to allow drugs in higher concentrations, and those that may otherwise be excluded, to reach the brain.” 

The study, “Blood-Brain Barrier Opening in Alzheimer’s Disease Using MR-guided Focused Ultrasound,” was conducted at Sunnybrook Health Sciences Centre in Toronto under the direction of Nir Lipsman, MD, PhD, Director of the Harquail Centre for Neuromodulation, and used Insightec’s Exablate Neuro device. The Focused Ultrasound Foundation funded and facilitated the organization of the trial. 

Six Alzheimer’s Patients

Six Alzheimer’s patients, ages 50-85, underwent two noninvasive focused ultrasound procedures. For the first stage, focused ultrasound was applied in a small area of the brain to temporarily open the BBB. In the second stage, approximately one month later, a similar procedure to the same patient targeted a larger area of the brain. It is important to note that this trial was a feasibility and safety study to see if focused ultrasound can be used to repeatedly open the BBB temporarily in these patients, and no drugs were administered in the study. 

Dr. Lipsman is presenting data from this study today at AAIC and taking part in a panel discussion regarding the application of focused ultrasound to treat or manage Alzheimer’s disease. Other panelists include Kullervo Hynynen, PhD (Sunnybrook Research Institute); Isabelle Aubert, PhD (Sunnybrook Research Institute); Cynthia Lemere, PhD (Brigham & Women’s Hospital/Harvard University); and Jürgen Götz, PhD (Queensland Brain Institute). 

Opening the BBB (Blood-Brain Barrier)

“By successfully opening the BBB safely and reversibly in patients with early to moderate Alzheimer’s disease, we can support the continued investigation of focused ultrasound as a potential novel treatment, and further study the delivery of therapies that otherwise cannot access the brain,” said Dr. Lipsman. “While it is still early in development, focused ultrasound may in the future provide a noninvasive, effective way of delivering large molecules such as antibodies directly to the brain to help patients with Alzheimer’s.” 

The next phase will investigate the safety and efficacy of using focused ultrasound to breach the BBB in a larger group of patients with Alzheimer’s in a Phase 2a trial beginning this fall. 

“This research using Insightec’s Exablate Neuro device is truly groundbreaking as it explores a new application for focused ultrasound,” says Maurice R. Ferré, MD, Insightec’s CEO and Chairman of the Board of Directors. “The disruption of the BBB has the potential to break down the barriers to treatment options in the brain with the promise to help millions of patients around the globe.” 

Focused Ultrasound Therapy for Alzheimer's

Focused ultrasound is an early-stage, non-invasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with Alzheimer’s disease. This novel technology focuses beams of ultrasonic energy precisely and accurately on targets deep in the brain without damaging surrounding normal tissue. Where the beams converge, the ultrasound produces a variety of therapeutic effects without incisions or radiation. 

Currently, there is no cure for Alzheimer’s and few disease modifying therapies. Potentially promising drug and antibody therapies are often limited by their inability to efficiently cross the blood-brain barrier (BBB), a naturally occurring barrier of cells that inhibits the diffusion of drugs or toxins into the central nervous system. 

Promising preclinical studies have demonstrated the potential of focused ultrasound to enhance the delivery of therapeutic drugs or antibodies to the brain. Focused ultrasound in combination with microbubbles can safely open the BBB and enable enhanced delivery of anti-amyloid antibodies to the brain. Studies suggest that this method can reduce the number of plaques and improve cognition in Alzheimer’s disease models. Furthermore, focused ultrasound and microbubbles alone (no antibodies) have had similar effects in two different Alzheimer’s models. 

Based on this preclinical evidence, this human trial investigating repeated, temporary opening of the BBB in patients with mild to moderate Alzheimer’s disease was completed. 

Advantages

  • Focused ultrasound is non-invasive – no incisions, holes in the skull, electrodes in the brain – and therefore has reduced risk for infection and blood clots.
  • Precise targeting minimizes damage to non-targeted healthy brain.
  • Treatment can be a complement to drug therapy, enabling enhanced delivery of disease-modifying therapies into the brain via temporary opening of the blood-brain barrier.

Helpful Links


See here for a list of treatment sites

See here for a list of clinical trials sites
See here for a list of laboratory research sites


Monday, September 19, 2011

New way for treating Alzheimer's disease

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Examiner.com
Ruben Dagda, Pittsburgh Medical Technology Examiner

Making the blood brain barrier more permeable may be the answer

Although there is currently no cure for treating Parkinson's and Alzheimer's disease, a preclinical study published yesterday at the prestigious Journal of Neuroscience may revolutionize the way patients will be treated in the US. Currently, one of the major impediments for treating many neurodegenerative diseases is the fact that the blood brain barrier is highly impermeable to most FDA approved and experimental drugs. Therefore, only a small fraction of the drug reaches the brain and has a therapeutic effect.

However, scientists from Cornell University discovered a way to make the blood brain barrier more permeable so that the brain absorbs a higher amount of therapeutic drugs: by using adenosine agonists. In brief, scientists discovered that mice intravenously injected with drugs that stimulate adenosine receptors (NECA) were able to accumulate a higher amount of an experimental sugar molecule (dextran) in the brain upto three times more compared to untreated animals. The modified sugar stayed in the brain upto 24 hrs. following a single intravenous injection of the adenosine receptor agonist drug. The effect of the drugs on the blood brain barrier is specific for adenosine receptors since mice that lacked adenosine receptors did not accumulate the dextran in the brain.

What is the medical relevance of this study?

A pathological hallmark of Alzheimer's disease is that patients accumulate protein garbage in neurons called beta-amyloid and tau protein which is associated with the destruction of memory neurons. Using a mouse model of Alzheimer's disease, the scientists showed that mice co-injected with adenosine agonists and with beta amyloid busters (a monoclonal antibody called 6E10) were able to bind to beta amyloid deposits in mice. This experiment is a proof of principle for using drugs that can make the blood brain barrier and with FDA approved drugs for Alzheimer's disease such as acetycholinesterase inhibitors. This study is promising and can lead to the creation of new revolutionary therapies for treating Alzheimer's disease.

Final remarks-

Approximately about 5.5 million people are afflicted with Alzheimer's and Parkinson's disease in the US. Many patients over 65 years of age are relegated to spending their final days of life in nursing homes or are cared by family members which can be a great economic and emotional burden.

There is a great need for finding safe and efficient techniques to administer drugs that can penetrate the blood brain barrier in high concentrations. Nowadays, some patients undergo highly invasive techniques such as direct injections of drugs into the ventricles of the brain, epidural injections or installing intracranial pumps to treat neurodegenerative diseases. Also, most drugs need to be chemically modified so that it can reach the blood brain barrier but renders the drug also capable to concentrate in unwanted tissues.

But what if we can avoid all this hassle and inconvenience of undergoing painful surgical procedures or spending a high amount of money on drugs that do not reach the brain? For instance about less than 10% of Parkinson's disease drugs such as Levodopa in combination with Carbidopa reach the brain while the rest is metabolized and wasted in Parkinson's disease patients. The solution proposed by the authors could bring down the costs of anti-neurodegenerative drugs and increase patient compliance.

The only downside is that patients will not be able to drink coffee or other caffeinated products if adenosine analogues or the FDA approved Lexiscan is used as treatment for Parkinson's and Alzheimer's.


References:

Carman, A., Mills, J. Krenz, A., Kim, D. Bynoe, M. Adenosine receptor signaling modulates permeability of the blood-brain barrier, 2011, The Journal of Neuroscience 31(37): 13272-13280.

Did you find this article interesting? then share my article with friends, send me a comment or follow Alzheimers1 on twitter.
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info